Vaccination against meningococcal disease starts for teens aged 14 to 18 This spring, about 860,000 young people in the Netherlands will receive an invitation for a vaccination against meningococcal disease.
RIVM designated as WHO Collaborating Centre Antimicrobial Resistance Epidemiology and Surveillance AMR is one of the major global challenges in infectious disease control.
RIVM researchers win best paper award of the journal Risk Analysis RIVM researchers Arie Havelaar and Arno Swart received the prestigious Best Paper Award 2014 of the Society for Risk Analysis.